Showing 2381-2390 of 10613 results for "".
Hormonal Acne Treatment Options
https://practicaldermatology.com/conferences/maui-derm-2022/hormonal-acne-treatment-options/20053/All acne is hormonal acne, says Julie C. Harper, MD. She discusses her approach to treating acne in preadolescents, adolescents, and male and female patients. From the role of oral contraceptives for women to the new topical clascoterone option, she says there are a number of safe and effective treaAn Update on Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/an-update-on-neuromodulators-and-fillers/19983/Suneel Chilukuri, MD discusses daxibotulinumtoxinA and its potential for longer lasting results. He also reviews newly available fillers and specific options for various areas of the face. Plus, he talks about low-cost options and how he’s using devices like SkinPen.Managing Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.Nailed It: Foods for Hair and Nails
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nailed-it-foods-for-hair-and-nails/19932/Zoe Draelos, MD is nuts about natural sources of nutrition and has some berry good news for those interested in alternative to supplements for the hair and nails. Hint: Not everyone needs supplements, she says.Patients types that may be a great fit for ILUMYA™
https://practicaldermatology.com/topics/psoriasis/patients-types-that-may-be-a-great-fit-for-ilumya/19859/See how ILUMYA™ is a treatment option for a diverse range of patients with moderate-to-severe plaque psoriasis, including bio-naive and bio-experienced patients, and those aged 65 years or older.DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisDERM2020 NP/PA CME Conference Thank You from DEF President Joe Gorelick, MSN, FNP-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-nppa-cme-conference-thank-you/19837/Joe Gorelick thanks the participants for DERM2020 Session 1 – all live webinars from August 6 – 11, 2020!DermWireTV: Dermatology Moves Beyond the COVID-19 Crisis
https://practicaldermatology.com/topics/practice-management/dermwiretv-dermatology-moves-beyond-the-covid-19-crisis/19815/This special edition of DermWireTV takes a look at the dermatology space as offices reopen. Includes updates on disease spread from WHO, advice on PCR and antibody testing, as well as tips for reopening from Suneel Chilukuri, MD (Refresh Dermatology) and Kimberly Campbell. Plus, Amy Forman Taub, MDNovel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical retiAtopic Dermatitis: Rethinking the “Typical” Patient
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-rethinking-the-typical-patient/19666/It's possible to make generalities about the experience of atopic dermatitis, but it's increasingly clear that there is no "typical" patient. Zelma Chiesa Fuxench, MD discusses the latest findings on the signs and symptoms of AD and the populations affected.